The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Acquired Immunodeficiency Syndrome-Global Market Insights and Sales Trends 2025
Synopsis
Acquired immunodeficiency syndrome (AIDS) is one of the most widespread, catastrophic, and incurable diseases among humans in the world. According to a report published by the World Health Organization (WHO) in 2013, deaths caused by HIV ranked sixth in the total number of deaths in the world. Human immunodeficiency virus (HIV) presents itself as a complex mixture of symptoms, all related to severe immune compromise, while AIDS is an advanced stage of HIV infection.
The global Acquired Immunodeficiency Syndrome market size is expected to reach US$ 1962.2 million by 2029, growing at a CAGR of 3.6% from 2023 to 2029. The market is mainly driven by the significant applications of Acquired Immunodeficiency Syndrome in various end use industries. The expanding demands from the Hospital Pharmacy, Retail Pharmacy and Others,, are propelling Acquired Immunodeficiency Syndrome market. Nucleoside Reverse Transcriptase Inhibitors (NRTIs), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Acquired Immunodeficiency Syndrome, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Acquired Immunodeficiency Syndrome market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Acquired Immunodeficiency Syndrome market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Acquired Immunodeficiency Syndrome sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Acquired Immunodeficiency Syndrome covered in this report include Takeda, AstraZeneca Eli Lilly and Company, Merck KGaA, Sanofi, Pfizer, Amgen, Biogen, Novartis and Actelion, etc.
The global Acquired Immunodeficiency Syndrome market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Takeda
AstraZeneca Eli Lilly and Company
Merck KGaA
Sanofi
Pfizer
Amgen
Biogen
Novartis
Actelion
Daiichi Sankyo Company
Global Acquired Immunodeficiency Syndrome market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Acquired Immunodeficiency Syndrome market, Segment by Type:
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Global Acquired Immunodeficiency Syndrome market, by Application
Hospital Pharmacy
Retail Pharmacy
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Acquired Immunodeficiency Syndrome companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Acquired immunodeficiency syndrome (AIDS) is one of the most widespread, catastrophic, and incurable diseases among humans in the world. According to a report published by the World Health Organization (WHO) in 2013, deaths caused by HIV ranked sixth in the total number of deaths in the world. Human immunodeficiency virus (HIV) presents itself as a complex mixture of symptoms, all related to severe immune compromise, while AIDS is an advanced stage of HIV infection.
The global Acquired Immunodeficiency Syndrome market size is expected to reach US$ 1962.2 million by 2029, growing at a CAGR of 3.6% from 2023 to 2029. The market is mainly driven by the significant applications of Acquired Immunodeficiency Syndrome in various end use industries. The expanding demands from the Hospital Pharmacy, Retail Pharmacy and Others,, are propelling Acquired Immunodeficiency Syndrome market. Nucleoside Reverse Transcriptase Inhibitors (NRTIs), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Acquired Immunodeficiency Syndrome, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Acquired Immunodeficiency Syndrome market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Acquired Immunodeficiency Syndrome market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Acquired Immunodeficiency Syndrome sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Acquired Immunodeficiency Syndrome covered in this report include Takeda, AstraZeneca Eli Lilly and Company, Merck KGaA, Sanofi, Pfizer, Amgen, Biogen, Novartis and Actelion, etc.
The global Acquired Immunodeficiency Syndrome market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Takeda
AstraZeneca Eli Lilly and Company
Merck KGaA
Sanofi
Pfizer
Amgen
Biogen
Novartis
Actelion
Daiichi Sankyo Company
Global Acquired Immunodeficiency Syndrome market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Acquired Immunodeficiency Syndrome market, Segment by Type:
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Global Acquired Immunodeficiency Syndrome market, by Application
Hospital Pharmacy
Retail Pharmacy
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Acquired Immunodeficiency Syndrome companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Acquired Immunodeficiency Syndrome
1.1 Acquired Immunodeficiency Syndrome Market Overview
1.1.1 Acquired Immunodeficiency Syndrome Product Scope
1.1.2 Acquired Immunodeficiency Syndrome Market Status and Outlook
1.2 Global Acquired Immunodeficiency Syndrome Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Acquired Immunodeficiency Syndrome Market Size by Region (2018-2029)
1.4 Global Acquired Immunodeficiency Syndrome Historic Market Size by Region (2018-2023)
1.5 Global Acquired Immunodeficiency Syndrome Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Acquired Immunodeficiency Syndrome Market Size (2018-2029)
1.6.1 North America Acquired Immunodeficiency Syndrome Market Size (2018-2029)
1.6.2 Europe Acquired Immunodeficiency Syndrome Market Size (2018-2029)
1.6.3 Asia-Pacific Acquired Immunodeficiency Syndrome Market Size (2018-2029)
1.6.4 Latin America Acquired Immunodeficiency Syndrome Market Size (2018-2029)
1.6.5 Middle East & Africa Acquired Immunodeficiency Syndrome Market Size (2018-2029)
2 Acquired Immunodeficiency Syndrome Market by Type
2.1 Introduction
2.1.1 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
2.1.2 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
2.2 Global Acquired Immunodeficiency Syndrome Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Acquired Immunodeficiency Syndrome Historic Market Size by Type (2018-2023)
2.2.2 Global Acquired Immunodeficiency Syndrome Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Acquired Immunodeficiency Syndrome Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Acquired Immunodeficiency Syndrome Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Acquired Immunodeficiency Syndrome Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Acquired Immunodeficiency Syndrome Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Acquired Immunodeficiency Syndrome Revenue Breakdown by Type (2018-2029)
3 Acquired Immunodeficiency Syndrome Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacy
3.1.2 Retail Pharmacy
3.1.3 Others
3.2 Global Acquired Immunodeficiency Syndrome Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Acquired Immunodeficiency Syndrome Historic Market Size by Application (2018-2023)
3.2.2 Global Acquired Immunodeficiency Syndrome Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Acquired Immunodeficiency Syndrome Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Acquired Immunodeficiency Syndrome Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Acquired Immunodeficiency Syndrome Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Acquired Immunodeficiency Syndrome Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Acquired Immunodeficiency Syndrome Revenue Breakdown by Application (2018-2029)
4 Acquired Immunodeficiency Syndrome Competition Analysis by Players
4.1 Global Acquired Immunodeficiency Syndrome Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Acquired Immunodeficiency Syndrome as of 2022)
4.3 Date of Key Players Enter into Acquired Immunodeficiency Syndrome Market
4.4 Global Top Players Acquired Immunodeficiency Syndrome Headquarters and Area Served
4.5 Key Players Acquired Immunodeficiency Syndrome Product Solution and Service
4.6 Competitive Status
4.6.1 Acquired Immunodeficiency Syndrome Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Takeda
5.1.1 Takeda Profile
5.1.2 Takeda Main Business
5.1.3 Takeda Acquired Immunodeficiency Syndrome Products, Services and Solutions
5.1.4 Takeda Acquired Immunodeficiency Syndrome Revenue (US$ Million) & (2018-2023)
5.1.5 Takeda Recent Developments
5.2 AstraZeneca Eli Lilly and Company
5.2.1 AstraZeneca Eli Lilly and Company Profile
5.2.2 AstraZeneca Eli Lilly and Company Main Business
5.2.3 AstraZeneca Eli Lilly and Company Acquired Immunodeficiency Syndrome Products, Services and Solutions
5.2.4 AstraZeneca Eli Lilly and Company Acquired Immunodeficiency Syndrome Revenue (US$ Million) & (2018-2023)
5.2.5 AstraZeneca Eli Lilly and Company Recent Developments
5.3 Merck KGaA
5.3.1 Merck KGaA Profile
5.3.2 Merck KGaA Main Business
5.3.3 Merck KGaA Acquired Immunodeficiency Syndrome Products, Services and Solutions
5.3.4 Merck KGaA Acquired Immunodeficiency Syndrome Revenue (US$ Million) & (2018-2023)
5.3.5 Sanofi Recent Developments
5.4 Sanofi
5.4.1 Sanofi Profile
5.4.2 Sanofi Main Business
5.4.3 Sanofi Acquired Immunodeficiency Syndrome Products, Services and Solutions
5.4.4 Sanofi Acquired Immunodeficiency Syndrome Revenue (US$ Million) & (2018-2023)
5.4.5 Sanofi Recent Developments
5.5 Pfizer
5.5.1 Pfizer Profile
5.5.2 Pfizer Main Business
5.5.3 Pfizer Acquired Immunodeficiency Syndrome Products, Services and Solutions
5.5.4 Pfizer Acquired Immunodeficiency Syndrome Revenue (US$ Million) & (2018-2023)
5.5.5 Pfizer Recent Developments
5.6 Amgen
5.6.1 Amgen Profile
5.6.2 Amgen Main Business
5.6.3 Amgen Acquired Immunodeficiency Syndrome Products, Services and Solutions
5.6.4 Amgen Acquired Immunodeficiency Syndrome Revenue (US$ Million) & (2018-2023)
5.6.5 Amgen Recent Developments
5.7 Biogen
5.7.1 Biogen Profile
5.7.2 Biogen Main Business
5.7.3 Biogen Acquired Immunodeficiency Syndrome Products, Services and Solutions
5.7.4 Biogen Acquired Immunodeficiency Syndrome Revenue (US$ Million) & (2018-2023)
5.7.5 Biogen Recent Developments
5.8 Novartis
5.8.1 Novartis Profile
5.8.2 Novartis Main Business
5.8.3 Novartis Acquired Immunodeficiency Syndrome Products, Services and Solutions
5.8.4 Novartis Acquired Immunodeficiency Syndrome Revenue (US$ Million) & (2018-2023)
5.8.5 Novartis Recent Developments
5.9 Actelion
5.9.1 Actelion Profile
5.9.2 Actelion Main Business
5.9.3 Actelion Acquired Immunodeficiency Syndrome Products, Services and Solutions
5.9.4 Actelion Acquired Immunodeficiency Syndrome Revenue (US$ Million) & (2018-2023)
5.9.5 Actelion Recent Developments
5.10 Daiichi Sankyo Company
5.10.1 Daiichi Sankyo Company Profile
5.10.2 Daiichi Sankyo Company Main Business
5.10.3 Daiichi Sankyo Company Acquired Immunodeficiency Syndrome Products, Services and Solutions
5.10.4 Daiichi Sankyo Company Acquired Immunodeficiency Syndrome Revenue (US$ Million) & (2018-2023)
5.10.5 Daiichi Sankyo Company Recent Developments
6 North America
6.1 North America Acquired Immunodeficiency Syndrome Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Acquired Immunodeficiency Syndrome Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Acquired Immunodeficiency Syndrome Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Acquired Immunodeficiency Syndrome Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Acquired Immunodeficiency Syndrome Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Acquired Immunodeficiency Syndrome Market Dynamics
11.1 Acquired Immunodeficiency Syndrome Industry Trends
11.2 Acquired Immunodeficiency Syndrome Market Drivers
11.3 Acquired Immunodeficiency Syndrome Market Challenges
11.4 Acquired Immunodeficiency Syndrome Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
